1.0600
07-October-24 15:59:55
15 minutes delayed
Stocks
-0.0900
-7.83%
Today's range
1.0600 - 1.1700
ISIN
N/A
Source
NASDAQ
IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine
09 Dec 2021 11:05:00 By Nasdaq GlobeNewswire
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial
06 Dec 2021 08:00:04 By Nasdaq GlobeNewswire
IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
09 Nov 2021 11:06:22 By Nasdaq GlobeNewswire